Investment Rating - The report assigns a "Strong Buy" rating to the company, indicating a positive outlook on its future performance [2][10]. Core Insights - The company is positioned as a leader in the domestic pharmaceutical industry, accelerating its innovation transformation. It has developed significant products such as Lijuzhiyuan, Shenqi Fuzheng Injection, and others, with revenue growth from 1.18 billion to 11.81 billion from 2000 to 2024, reflecting a compound annual growth rate (CAGR) of over 10% [7][16]. - The company is expected to enter a low base period for its existing business after risk release in 2026, with stable growth across its chemical and traditional Chinese medicine sectors [9][38]. - The innovation business is anticipated to see accelerated growth, with a projected revenue of 4.775 billion by 2030, reflecting a CAGR of 147% from 2025 to 2030 [9][37]. - The raw materials and traditional Chinese medicine segments are expected to provide stable cash flow, with a recovery in demand for key products [9][38]. Summary by Sections Company Overview - The company has evolved into a large pharmaceutical group covering research, production, and commercialization, focusing on areas such as digestive health, reproductive health, and mental health [15][16]. - It has a strong foundation in innovation, with a diverse pipeline and a commitment to high clinical value products [27][28]. Existing Business - The existing product lines are expected to stabilize post-2026, with only specific products facing risks, while others have cleared potential issues [9][41]. - The company has maintained balanced growth in its chemical and traditional Chinese medicine businesses, avoiding reliance on any single product [38]. Innovation Business - The company is set to benefit from a peak in new product launches starting in 2025, with several innovative products expected to enter the market [28][36]. - The focus on high-barrier complex formulations and high clinical value products is expected to drive significant revenue growth [34][37]. Financial Projections - The projected net profits for 2025-2027 are 20.22 billion, 20.78 billion, and 23.78 billion respectively, with corresponding growth rates of -1.9%, +2.8%, and +14.4% [10][37]. - The current stock price corresponds to a price-to-earnings (PE) ratio of only 15 times for 2026, indicating potential undervaluation [10][37].

Investment Rating - The report assigns a "Strong Buy" rating to the company, with a target price of 55.67 CNY per share based on a comprehensive valuation of 494.35 billion CNY for the company in 2026 [2][10]. Core Insights - The company is positioned as a leading player in the domestic pharmaceutical industry, accelerating its innovation transformation. It has developed significant products such as Lijuzhiyuan, Shenqi Fuzheng Injection, and others, with a revenue growth from 1.18 billion CNY in 2000 to 11.81 billion CNY in 2024, reflecting a compound annual growth rate (CAGR) of over 10% [7][16]. - The company’s existing business is expected to enter a low base period after risk release in 2026, with stable growth across its chemical and traditional Chinese medicine segments [9][38]. - The innovation business is anticipated to see accelerated growth, with a projected revenue of 4.775 billion CNY from innovative products by 2030, reflecting a CAGR of 147% from 2025 to 2030 [8][37]. Summary by Sections Company Overview - The company has evolved into a large pharmaceutical group covering drug research, production, and commercialization, focusing on areas such as digestive health, reproductive health, and mental health [15][16]. - It has a strong foundation in innovation, having established various research platforms and a diverse product pipeline [26][27]. Existing Business - The company’s chemical and traditional Chinese medicine businesses have maintained balanced growth, with only specific products facing risks, while others have cleared potential risks [38][41]. - The company’s revenue from traditional Chinese medicine is showing signs of recovery, with key products like Shenqi Fuzheng Injection benefiting from increased demand [9][41]. Innovation Business - The company is set to launch several innovative products starting in 2026, with a strong focus on high-value therapeutic areas [28][34]. - The innovative pipeline includes products in digestive health, mental health, and reproductive health, which are expected to drive significant revenue growth [8][28]. Financial Projections - The company’s projected net profits for 2025, 2026, and 2027 are 20.22 billion CNY, 20.78 billion CNY, and 23.78 billion CNY, respectively, with growth rates of -1.9%, +2.8%, and +14.4% [10][37]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 15 times for 2026, indicating a favorable valuation compared to peers [10][37].

Core Viewpoint - Lijun Group is a leading domestic pharmaceutical company in China, accelerating its innovation transformation and benefiting from the rise of the Chinese pharmaceutical industry [2] Existing Business - The company's revenue grew from 1.18 billion to 11.81 billion from 2000 to 2024, with a compound annual growth rate (CAGR) exceeding 10%. The net profit, excluding non-recurring items, increased from 10.38 million to 1.98 billion, with a CAGR of 24.4% [2] - The chemical and traditional Chinese medicine segments have maintained balanced growth, with performance not overly reliant on any single product. Despite facing price reductions and policy restrictions, the company has managed to achieve stable performance over the past 20 years [2] - By 2026, the company expects to enter a low base period for its existing formulation business, as most risks have been cleared except for the Aprazole series and the Leuprolide microsphere [2] Innovation Business - Lijun has developed strong core competencies, including commercial conversion capabilities and a leading microsphere technology platform. The company focuses on clinical value and product iteration in core areas such as digestion, GnRH/reproductive assistance, and mental health [3] - The revenue from innovative products is expected to accelerate, with projected revenue reaching 4.775 billion by 2030, reflecting a compound annual growth rate of 147% from 2025 to 2030 [3] Raw Materials and Traditional Chinese Medicine - The raw materials business has successfully transitioned from bulk raw materials to high-end specialty raw materials, expanding from domestic to international markets [4] - The traditional Chinese medicine segment, primarily driven by core products like the Shenqi Fuzheng injection and antiviral granules, reported revenue of 800 million in the first half of 2025, an 8% year-on-year increase [4] - The overall traditional Chinese medicine business is showing a recovery growth trend, with gross margins gradually increasing [4] Investment Recommendations - The company is expected to achieve net profits of xx, xx, and xx billion from 2025 to 2027, with year-on-year growth rates of xx%, xx%, and xx% respectively. The current stock price corresponds to a price-to-earnings ratio of only xx times for 2026 [4] - As a representative of the transformation from generic to innovative drugs, Lijun is entering a phase of harvesting from its innovation pipeline. The company is valued using a segmented approach, with a reasonable valuation of xx billion for its main business and xx billion for its innovative drug business, leading to a comprehensive valuation of xx billion and a target stock price of xx yuan per share [4]

Group 1: R&D Progress and Market Position - The LZM012 project has completed Phase III clinical trials for psoriasis and ankylosing spondylitis, with a formal market application expected next month for psoriasis and in the first half of next year for ankylosing spondylitis [2][3] - LZM012 is the first domestic Phase III study targeting psoriasis with PASI100 as the primary endpoint, showing superior efficacy compared to existing treatments, with fewer administration cycles and lower overall costs [2][3] - The JP-1366 tablet of the P-CAB product has been submitted for market approval, with the injection form entering Phase II clinical trials, capitalizing on the growing P-CAB market projected to reach approximately CNY 1.25 billion in 2024, an 81% year-on-year increase [3][4] Group 2: Strategic Product Development - The company is focusing on the schizophrenia long-acting injection market, with the recently approved aripiprazole microsphere being the first of its kind in China, included in the 2025 guidelines for schizophrenia treatment [4][5] - The company is advancing a new generation KCNQ2/3 activator, NS-041, which is a first-class new drug with unique molecular design, targeting both epilepsy and depression indications [5] - The company has established a comprehensive product pipeline for GnRH-a long-acting release formulations, with the approval of the first microsphere product and plans for further submissions, enhancing treatment options for various conditions [6][7] Group 3: Financial Health and Strategic Acquisitions - The company maintains a robust cash reserve, allowing for dividends, buybacks, daily operations, R&D investments, and potential strategic acquisitions [8][9] - A planned acquisition of a Vietnamese company is underway, marking the first acquisition of a Vietnamese pharmaceutical company by a Chinese enterprise, with ongoing compliance with local regulations [9] - The company aims to focus on strategic partnerships in areas such as digestion, mental health, cardiovascular, metabolic, and autoimmune diseases, targeting projects with patent barriers and commercialization potential [9]

Core Viewpoint - Lijun Group (000513) focuses on the development of microsphere technology, particularly in the areas of GnRH-α and mental health products, with significant advancements in long-acting formulations and international market expansion [1] Group 1: Product Development - The core product, Leuprolide microsphere (one-month release), is the first GnRH-α long-acting formulation approved by the FDA based on individual drug guidelines [1] - The injectable Triptorelin microsphere has received approval for prostate cancer and is expected to be approved for endometriosis in 2024, with ongoing Phase III clinical trials for central precocious puberty [1] - A three-month release Leuprolide microsphere application has been submitted, with expected approval in 2026 [1] - The company is also developing a microsphere formulation of Ganirelix, which currently has no market presence globally [1] Group 2: Mental Health Product Line - The company has launched an injectable Aripiprazole microsphere, which offers the longest dosing interval (once a month) for schizophrenia treatment globally [1] - Additional products like Brexpiprazole microsphere are in development to strengthen the long-acting product line for mental health [1] Group 3: Market Expansion in Vietnam - The acquisition of Imexpharm in Vietnam is under approval, with the company showing over 20% growth in revenue, profit, and EBITDA in the third quarter [1] - Imexpharm has the largest EU-GMP product line in Vietnam, and both companies are planning product and process transfers to leverage Imexpharm's established market channels and EU-GMP certification for expanding innovative drug products overseas [1]

Financial Performance - The company achieved a total revenue of 91.16 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 0.38% [2] - The net profit attributable to the parent company, after deducting non-recurring items, was 4.98 billion yuan, reflecting a year-on-year increase of 17.12% [2] - The formulation segment saw growth in major categories such as digestive, mental health, and traditional Chinese medicine, contributing to overall revenue stability [2] R&D Progress - The company has made significant advancements in key projects, including the submission of the P-CAB tablet for market approval and the completion of Phase II clinical trials for the injection form [3][8] - The IL-17A/F project for psoriasis and ankylosing spondylitis has completed Phase III clinical trials, with data expected to be submitted for market approval by the end of the year [4] - The NS-041 tablet for epilepsy and depression has entered Phase II clinical trials, with promising results in preclinical models [3] Market Strategy - The company plans to leverage its established sales channels in the digestive field to ensure rapid market penetration for new products like JP-1366, which is projected to achieve a sales figure of approximately 12.5 billion yuan in 2024, marking an 81% year-on-year growth [8] - The company is focusing on international expansion, particularly in Vietnam, where it aims to utilize the existing EU-GMP certified product lines of Imexpharm to enhance its market presence [6] Future Outlook - The company anticipates a stable revenue trend for the year, with profit growth expected to outpace revenue growth [11] - A clear roadmap for the launch of innovative drugs has been established, with multiple products set to enter the market over the next few years, including the IL-17A/F project and various formulations in the digestive and mental health sectors [9][10] - The company has committed to a high dividend payout, having repurchased shares worth 17.2 billion yuan and distributed nearly 60 billion yuan in dividends from 2020 to 2024 [13]